UK markets close in 1 hour 49 minutes
  • FTSE 100

    +46.94 (+0.71%)
  • FTSE 250

    +15.92 (+0.08%)
  • AIM

    -1.33 (-0.11%)

    +0.0009 (+0.08%)

    -0.0002 (-0.01%)

    +987.84 (+2.86%)
  • CMC Crypto 200

    +10.45 (+1.06%)
  • S&P 500

    -6.21 (-0.16%)
  • DOW

    +8.26 (+0.03%)

    +0.27 (+0.45%)

    +1.00 (+0.06%)
  • NIKKEI 225

    -255.33 (-0.86%)

    -356.71 (-1.21%)
  • DAX

    +84.67 (+0.60%)
  • CAC 40

    +33.80 (+0.58%)

Ineos gives Oxford University £100m for antibiotic resistance research institute

Eleanor Busby, PA Education Correspondent
·3-min read

The University of Oxford has been given £100 million – one of the largest donations in its history – for a new institute that aims to combat the growing issue of resistance to antibiotics.

The gift from chemicals giant Ineos will be used to fund antimicrobial research at the institution, which played a key role in the origin of antibiotics after its academics discovered penicillin in the 1940s.

Researchers will seek to develop new drugs for animals and humans, as well as promote more responsible use of the antibiotics we have, following a rise in antibiotic-resistant “superbugs”.

It is estimated that by 2050, up to 10 million deaths each year could be caused by antibiotics and other antimicrobial drugs no longer being effective at treating common diseases.

Oxford’s vice chancellor Professor Louise Richardson said immediate action to address the issue was “imperative” as she warned it would be “cataclysmic” for surgeries if infection could not be prevented by antibiotics.

She told the PA news agency: “I think that the pandemic has shown us just the extraordinary high costs if you ignore a problem that is potentially headed your way.

“We certainly knew that there was a high potential for another pandemic, we were reminded of that many times, and yet we were caught unprepared.

“We know that human antibiotics are, with every passing year, becoming fewer and fewer because of the growth of resistance so it’s absolutely imperative that we act, and the impact of being unprepared for the pandemic I think reinforces the importance of acting before it’s too late. And it may seem very costly to do all this research now but it’s nothing on the cost of failure to act.”

“Every time you have surgery, the biggest risk is infection, so you get an antibiotic to prevent that. Imagine if you couldn’t prevent infection, it would be cataclysmic for so many surgeries,” she warned.

Sir Jim Ratcliffe, founder and chairman of Ineos, said he is “excited” to partner with the university “to accelerate progress in tackling this urgent global challenge”.

Prof Richardson said the donation to the university was “wonderfully generous” and she added that it felt “entirely appropriate” that Oxford would be “in the vanguard” of the search for antimicrobial resistance after the institution created penicillin in the last century which saved millions of lives.

When asked about the argument that the pandemic and its impact on the NHS should be the main focus of any additional funding right now, Prof Richardson said: “I think any philanthropist is entitled to decide for themselves what their money is going to be used for and personally I can’t think of something that will have greater societal impact than addressing the terrible problem of antimicrobial resistance.”

The university is planning to have more than 50 postdoctoral research scientists working at the Ineos Oxford Institute for Antimicrobial Resistance over the next five years, alongside a number of PhD students.

Surgeon David Sweetnam, adviser to the Ineos Oxford Institute, said: “If there is any positive lesson to be taken from the devastation of the Covid-19 pandemic, we’ve clearly seen that the only way out of such infectious disease crises is through brilliant scientific groundwork, laid well in advance.

“The vaccines which have been created in record time and which offer light at the end of the tunnel were developed using research conducted long before Covid-19 struck.

“It’s clear that we must be looking right now for new antibiotics with the same urgency as we have been for vaccines. The consequence of continued complacency doesn’t bear thinking about.”